My watch list  

12 Current news of BioNTech


You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
BioNTech and Pfizer test COVID-19 Vaccine Candidate in Germany

Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial Received


BioNTech SE and Pfizer Inc. announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 2/3 clinical trial in Germany for their BNT162b2 vaccine candidate. The study in Germany is part of the global pivotal Phase 2/3 program BioNTech and Pfizer initiated in ...


image description
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate

Doses expected to be delivered in 2020 and 2021


Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not ...


image description
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Efforts to manufacture the leading candidates, at risk, are gearing up


Pfizer Inc. and BioNTech SE announced preliminary U.S. data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at ...


image description
BioNTech to Raise USD 250 Million in Private Placement

The private placement includes an investment in ordinary shares and a investment in 4-year mandatory convertible notes


BioNTech SE announced a private investment of USD 250 million (EUR 223 million) by Temasek and other accredited investors. The private placement includes an investment of approximately USD 139 million in ordinary shares and a USD 112 million investment in 4-year mandatory convertible notes. “We ...


image description
Pfizer and BioNTech to Accelerate Global COVID-19 Vaccine Development


BioNTech SE and Pfizer Inc. disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on ...


image description
Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine


Pfizer Inc. and BioNTech SE announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and ...


image description
BioNTech receives USD 325 million

One of the largest private EU biotech funding events expands global shareholder base


BioNTech SE announced the completion of a USD 325 million Series B financing round, making it one of the largest single private funding rounds for a biotechnology company in European history. The fund raising was upsized and was led by Fidelity Management & Research Company with participation ...


Sanofi Invests EUR 80m in BioNTech


BioNTech AG announced that it has extended its research collaboration with Sanofi initiated in late 2015 and Sanofi is investing* EUR 80 million (approximately USD 91.5 million) in equity in BioNTech. Simultaneously BioNTech has entered into an agreement with Sanofi to co-develop the first cancer ...


BioNTech Secures USD 270 Million in Series A Financing


BioNTech AG announced it has completed a USD 270 million Series A round of financing. The Company previously completed a seed round fundraising in 2008 concurrent with its founding. The Series A round was led by the Redmile Group and joined by Janus Henderson Investors, Invus, Fidelity Management ...


Sanofi and BioNTech announce collaboration

Contains license agreement for cancer immunotherapy


Sanofi and BioNTech A.G. announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to five cancer ...


Page 1 From 2
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE